Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer

Annals of Oncology

Volumn 14, Issue 2, 2003, Pages 197-204

  Kruijtzer, C M F ^a   Boot, H ^a   Beijnen, J H ^a,b   Lochs, H L ^c   Parnis, F X ^d   Planting, A S T ^e   Pelgrims, J M G ^f   Williams, R ^g   Mathot R A A ^b   Rosing, H ^b   Schot, M E ^a   van Tinteren, H ^a   Schellens, J H M ^a,b  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Ashfold Cancer Center   (Australia)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f Stuivenberg General Hospital   (Belgium)

^g IVAX Research Inc   (United States)

Author keywords

Advanced gastric cancer; Chemotherapy; Cyclosporin A; Paclitaxel; Toxicity

Indexed keywords

ANTIALLERGIC AGENT; CISPLATIN; CLEMASTINE; CREMOPHOR; CYCLOSPORIN A; CYTOCHROME P450 3A; DEXAMETHASONE; DRUG VEHICLE; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; GRANISETRON; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; PAXORAL; PROTEIN INHIBITOR; PROTON PUMP INHIBITOR; RANITIDINE; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG INDICATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0037294483     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg078     Document Type: Article

References (35)

1. Cullinan SA, Moertel CG, Wienand HS et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994; 12: 412-416.
2. Wils JA, Klein HO, Wagener DJT et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
3. Webb A, Cunningham D, Scarffe H et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
4. Boot H, Cats A, Tonino S et al. Epirubicin, cisplatin and continuous 5-FU chemotherapy (ECF-regimen) in patients with cancer of the gastroesophageal junction and stomach. Gastroenterology 2002; 122 (4 Suppl): A-601 (Abstr W1281).
5. Ohtsu A, Boku N, Tamura F et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 4: 416-419.
6. Cascinu S, Ficarelli, Safi MA et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998; 9: 307-310.
7. Einzig AL, Lipsitz S, Wiernik PH et al. Phase II trial of Taxol in patients with adenocarcinoma of upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology Group (ECOG) results. Invest New Drugs 1995; 3: 223-227.
8. Yamada Y, Shirao K, Ohtsu A et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001; 12: 1133-1137.
9. Rougier P. Docetaxel delivers new management opportunities for gastro-intestinal carcinomas. Anticancer Drugs 1995; 6 (Suppl 4): 25-29.
10. Safran H, King TP, Choy H et al. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol 1997; 15: 901-907.
11. Bokemeyer C, Lampe CS, Clemens MR et al. Phase II trial of paclitaxel and weekly 24 hour infusion of 5-fluorouracil/folinic acid in patients with advanced gastric cancer. Anticancer Drugs 1997; 8: 396-399.
12. Kollmannsberger C, Quietzsch D, Haag C et al. A phase II study of paclitaxel, weekly 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 4: 458-462.
13. Philip PA, Zalupski MM, Gadgeel S et al. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol 1997; 24 (Suppl 19): 86-88.
14. Seidman AD, Hudis CA, Albanel J et al. Dose dense therapy with weekly 1 hour paclitaxel infusions in metastatic breast cancer. J Clin Oncol 1998; 16: 3353-3361.
15. Akerley W, Glantz M, Choy H et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998; 16: 153-158.
16. Akerley W, Herndon J, Egorin MJ et al. CALGB 9731: phase II study of weekly paclitaxel for advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999; 18: 462a (Abstr 1783).
17. Sparreboom A, Van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 1997; 94: 2031-2035.
18. Malingré MM, Beijnen JH, Schellens JHM. Oral delivery of taxanes. Invest New Drugs 2001; 19: 155-162.
19. van Asperen J, Van Tellingen O, Van der Valk MA et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice co-treated with cyclosporin A. Clin Cancer Res 1998; 4: 2293-2297.
20. Meerum Terwogt JM, Malingré MM, Beijnen JH et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res 1999; 5: 3379-3384.
21. Malingré MM, Beijnen JH, Rosing H et al. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 2001; 12: 351-358.
22. Liebmann JE, Cook JA, Lipschultz C et al. Cytotoxic studies of paclitaxel in human tumour cell lines. Br J Cancer 1993; 32: 235-242.
23. Raymond E, Hanauske A, Faivre SW et al. Effects of prolonged versus short-term exposure paclitaxel on human tumor colony-forming units. Anticancer Drugs 1997; 8: 379-385.
24. Malingré MM, Beijnen JH, Rosing H et al. A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 2001; 47: 347-354.
25. Therasse P, Arbuck SG, Eisenhauer E et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
26. Malingré MM, Meerum Terwogt JM, Beijnen JH et al. A Phase I and pharmacokinetic study of paclitaxel. J Clin Oncol 2000; 18: 2468-2475.
27. Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute. Bethesda, MD: National Cancer Institute 1998.
28. Huizing MT, Sparreboom A, Rosing H et al. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995; 674: 261-268.
29. Chan GL, Weinstein SS, Lefor WW et al. Relative performance of specific and nonspecific fluorescence polarization immunoassay for cyclosporin in transplant patients. Ther Drug Monit 1992; 14: 42-47.
30. Beal SL, Boeckman AJ, Sheiner LW. NONMEM Users guide Part VI: PREDPP guide. NONMEM Project GROUP, University of California, San Francisco, USA. San Francisco, CA: University of California 1992.
31. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
32. Huizing MT, Misser VH, Pieters RC et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
33. Huizing MT, Keung AC, Rosing H et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 1997; 15: 317-329.
34. Kruijtzer CM, Schellens JH, Mezger J et al. Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4508-4516.
35. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190.